The company is investing billions of dollars to construct a European biosimilar hub capable of supporting the rapid expansion ...

Bristol Myers Squibb is positioning arlo-cel for quadruple-class exposed patients, which could help reduce competition with ...

Months before the current biotech IPO boom, public investors began a more confident trek back into the sector, signaling the ...

As geopolitical tensions between the U.S. and China grow increasingly complicated, here are five alternative territories for ...

Watch this discussion on how GLP-1 drugs for obesity are changing the shape of U.S. healthcare. From direct-to-consumer portals to pharmacy deals, how these drugs reach patients is changing—and ...